AU2003292556B2 - Derivatives of prostaglandins for treating abdominal discomfort - Google Patents

Derivatives of prostaglandins for treating abdominal discomfort Download PDF

Info

Publication number
AU2003292556B2
AU2003292556B2 AU2003292556A AU2003292556A AU2003292556B2 AU 2003292556 B2 AU2003292556 B2 AU 2003292556B2 AU 2003292556 A AU2003292556 A AU 2003292556A AU 2003292556 A AU2003292556 A AU 2003292556A AU 2003292556 B2 AU2003292556 B2 AU 2003292556B2
Authority
AU
Australia
Prior art keywords
compound
prostaglandin
alkyl
hydroxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003292556A
Other languages
English (en)
Other versions
AU2003292556A1 (en
Inventor
Sachiko Kuno
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003292556(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of AU2003292556A1 publication Critical patent/AU2003292556A1/en
Application granted granted Critical
Publication of AU2003292556B2 publication Critical patent/AU2003292556B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2003292556A 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort Expired AU2003292556B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43646202P 2002-12-27 2002-12-27
US43646302P 2002-12-27 2002-12-27
US60/436,463 2002-12-27
US60/436,462 2002-12-27
PCT/JP2003/016857 WO2004060377A1 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Publications (2)

Publication Number Publication Date
AU2003292556A1 AU2003292556A1 (en) 2004-07-29
AU2003292556B2 true AU2003292556B2 (en) 2009-09-10

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003292556A Expired AU2003292556B2 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Country Status (15)

Country Link
US (3) US7795312B2 (enExample)
EP (2) EP2281564A3 (enExample)
JP (2) JP4889219B2 (enExample)
KR (2) KR20120045051A (enExample)
CN (1) CN1753680B (enExample)
AR (1) AR042670A1 (enExample)
AU (1) AU2003292556B2 (enExample)
BR (1) BRPI0317740B8 (enExample)
CA (1) CA2510051C (enExample)
ES (1) ES2591252T3 (enExample)
MX (1) MXPA05006981A (enExample)
NO (1) NO335441B1 (enExample)
NZ (1) NZ541110A (enExample)
TW (1) TWI336254B (enExample)
WO (1) WO2004060377A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
KR101466980B1 (ko) * 2005-04-12 2014-12-01 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자펌프 억제제의 병용
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013161973A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978284A1 (en) * 1997-11-28 2000-02-09 R-Tech Ueno, Ltd. Endothelin antagonist
WO2001076593A2 (en) * 2000-04-06 2001-10-18 Sucampo Ag Bile secretion promoting composition a 15-keto prostaglandin
AU2002348670A1 (en) * 2001-11-19 2003-06-10 Sucampo Ag PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
DE69130586T2 (de) 1990-05-01 1999-06-17 R-Tech Ueno, Ltd., Osaka Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
ATE402925T2 (de) 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
BR0209863A (pt) 2001-05-18 2004-06-08 Sucampo Ag Composição catártica
JP4786866B2 (ja) * 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978284A1 (en) * 1997-11-28 2000-02-09 R-Tech Ueno, Ltd. Endothelin antagonist
WO2001076593A2 (en) * 2000-04-06 2001-10-18 Sucampo Ag Bile secretion promoting composition a 15-keto prostaglandin
AU2002348670A1 (en) * 2001-11-19 2003-06-10 Sucampo Ag PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER

Also Published As

Publication number Publication date
EP1575596B1 (en) 2016-06-22
US20130217770A1 (en) 2013-08-22
WO2004060377A1 (en) 2004-07-22
US7795312B2 (en) 2010-09-14
NO20053623D0 (no) 2005-07-26
CN1753680B (zh) 2010-12-08
CA2510051C (en) 2016-07-05
BRPI0317740B1 (pt) 2018-09-18
BR0317740A (pt) 2005-11-22
NZ541110A (en) 2008-11-28
KR20050086950A (ko) 2005-08-30
AU2003292556A1 (en) 2004-07-29
AR042670A1 (es) 2005-06-29
MXPA05006981A (es) 2005-12-14
JP4889219B2 (ja) 2012-03-07
EP2281564A3 (en) 2012-09-05
EP1575596A1 (en) 2005-09-21
CN1753680A (zh) 2006-03-29
JP2006513232A (ja) 2006-04-20
US20040138308A1 (en) 2004-07-15
KR101164838B1 (ko) 2012-07-11
TWI336254B (en) 2011-01-21
ES2591252T3 (es) 2016-11-25
JP2012031202A (ja) 2012-02-16
TW200418491A (en) 2004-10-01
KR20120045051A (ko) 2012-05-08
NO20053623L (no) 2005-09-26
US20100298424A1 (en) 2010-11-25
BRPI0317740B8 (pt) 2021-05-25
CA2510051A1 (en) 2004-07-22
NO335441B1 (no) 2014-12-15
EP2281564A2 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
US20100298424A1 (en) Method for treating abdominal discomfort
EP1392318B1 (en) 15-keto-prostaglandins for treating drug-induced constipation
AU2008271982B2 (en) Pharmaceutical combination of NSAID and prostaglandin compound
AU2002251554A1 (en) Composition for Treating Drug-Induced Constipation
JP5294559B2 (ja) クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
AU2003274735B2 (en) Prostaglandin compounds for the treatment of obesity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired